Pemigatinib for FGFR-altered advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor (not blood cancer) that has spread or come back and cannot be surgically removed
- Your tumor must have a specific change (mutation or fusion) in the FGFR1, FGFR2, or FGFR3 gene
- You should be 18 or older and have a performance status that allows you to be up and about (ECOG 0-2)
- You must have no other standard treatment options, and you must not have taken a similar targeted drug before (like pemigatinib)
- You need to have had two scans (CT or MRI) at least 4 weeks apart showing the tumor is growing slowly but measurably (at least 0.1 mm per day)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—pemigatinib, which targets tumors with certain FGFR gene changes, and an immunotherapy drug that helps the immune system fight cancer—for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
This Phase 2 trial tests pemigatinib, a targeted medicine, for advanced or metastatic gastrointestinal (GI) cancers that have specific FGFR1–3 gene changes. It’s for people whose cancer has grown despite prior standard treatment, and who may benefit if their tumor has the right genetic change.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
This trial tests a pill called pemigatinib for people with bile duct cancer that has spread and has a specific gene change (FGFR2 fusion or rearrangement). It may slow or stop tumor growth. The study is for those whose cancer has progressed after at least one prior treatment.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
Hear when a new Solid Tumor, Miscellaneous trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.